Early Cholecystectomy for Acute Cholecystitis: Comprehensive 2025 Evidence Review | Medaptly

Early Cholecystectomy for Acute Cholecystitis: What the Evidence Shows

A synthesis of 10+ randomised trials and meta-analyses examining optimal surgical timing, safety outcomes, and clinical decision-making for patients with acute calculous cholecystitis — through 2025.

This is an original evidence synthesis. See References for source studies.

March 20, 2026 · 14 min read

One-Minute Takeaway

One-Minute Takeaway

Multiple meta-analyses of RCTs provide strong evidence that early cholecystectomy for acute cholecystitis is at least as safe as delayed surgery, with consistent reductions in total hospital stay and healthcare costs.
The landmark ACDC trial (n=618) found that surgery within 24 hours of admission reduced 75-day morbidity from 34.4% to 11.8% compared with an antibiotics-first strategy, with no increase in conversion rates or mortality.
Both the Tokyo Guidelines 2018 and the 2020 WSES guidelines now recommend early laparoscopic cholecystectomy for operable patients, though they differ on the precise timing window (within 72 hours vs. within 7 days of admission).
Approximately 10% of patients managed conservatively while awaiting delayed surgery experience treatment failure requiring emergency intervention — a risk that early surgery eliminates.
Evidence remains limited for patients with severe (Grade III) cholecystitis, significant comorbidities, and symptom duration beyond 10 days — these subgroups lack dedicated randomised trial data.

Why This Topic Matters

Acute calculous cholecystitis ranks among the most frequent surgical emergencies worldwide. Gallstone disease affects an estimated 10–15% of the adult population in Western countries, and between 1% and 4% of those individuals develop symptomatic complications each year. Acute cholecystitis accounts for the majority of gallstone-related hospital admissions, making the timing of cholecystectomy a decision that impacts healthcare systems on a massive scale.

Early cholecystectomy surgical timing decision for acute cholecystitis — Timing of surgery in acute cholecystitis remains a key clinical decision balancing operative risk with the costs of delayed care.

Despite decades of evidence favouring prompt surgical intervention, significant variation persists in clinical practice. Many centres still default to an antibiotics-first strategy followed by interval cholecystectomy 6–12 weeks later, often driven by logistical constraints, operating theatre availability, or surgeon preference rather than evidence. This gap between evidence and practice has prompted both the Tokyo Guidelines committee and the World Society of Emergency Surgery to issue increasingly direct recommendations in favour of early surgery. Understanding the current body of evidence is essential for any surgeon or emergency physician managing this common condition.

What Evidence Was Reviewed

This synthesis draws on multiple levels of evidence addressing the timing of cholecystectomy in acute cholecystitis. The evidence base includes several Cochrane reviews, large multicentre RCTs, updated meta-analyses incorporating over 15 randomised trials, and two major international clinical practice guidelines (Tokyo Guidelines 2018 and WSES 2020). Studies span three decades but emphasis is placed on evidence published within the last ten years, which reflects current laparoscopic techniques and perioperative care standards.

Study	Design	n	Population	Key Finding	Quality
Gutt et al. 2013 (ACDC)	Multicentre RCT	618	Adults with AC, operable	Surgery ≤24 h reduced 75-day morbidity (11.8% vs 34.4%)	High
Cao et al. 2015 (MA)	Meta-analysis of 15 RCTs	NR	AC patients	Early LC reduced wound infections; no difference in BDI, mortality, conversion	Moderate
Gurusamy et al. 2013 (Cochrane)	SR/MA of 6 RCTs	488	AC fit for surgery	No difference in BDI or serious complications; shorter total stay with early LC	Moderate
Lyu et al. 2018 (MA)	Updated MA of RCTs	NR	AC patients	Early LC safe with shorter total stay; longer operative time	Moderate
Loozen et al. 2018 (CHOCOLATE)	Multicentre RCT	142	High-risk AC (APACHE II ≥7)	LC superior to percutaneous drainage even in high-risk patients	High
Pisano et al. 2020 (WSES Guidelines)	Guideline (GRADE)	NR	All ACC patients	ELC within 7 days recommended as standard of care	High
Okamoto et al. 2018 (TG18)	Guideline (consensus)	NR	All AC, severity-graded	Early LC recommended regardless of symptom duration; severity-stratified approach	High
Gallagher et al. 2019 (MA)	MA of economic analyses	NR	AC patients in RCTs	Early LC cost-effective; savings driven by reduced readmissions	Moderate
Shetty et al. 2025 (RCT)	Single-centre RCT	96	Adults with AC	Early LC safe; shorter stay despite longer operative time	Low
Salama et al. 2025 (SR)	Systematic review	NR	Conservatively managed AC	No reliable predictors of recurrence while awaiting surgery identified	Low
Multicentric WSES study 2023	Prospective observational	1117	AC, 79 centres in 19 countries	Earlier surgery (0–3 days) had fewer intraoperative complications than 8–10 days	Moderate

Key Findings on Early Cholecystectomy: Synthesised by Theme

Safety: Early Surgery Does Not Increase Major Complications

Across multiple meta-analyses pooling data from over a dozen RCTs, early laparoscopic cholecystectomy has been consistently associated with no statistically significant increase in bile duct injury, bile leakage, mortality, or conversion to open surgery when compared with delayed approaches. The Cochrane review by Gurusamy and colleagues, for example, found bile duct injury rates of 0.4% for early surgery versus 0.9% for delayed, with a Peto OR of 0.49 (95% CI 0.05–4.72) — a non-significant difference with wide confidence intervals reflecting the rarity of this outcome. Similarly, the Cao et al. meta-analysis of 15 RCTs reported no difference in mortality, bile duct injuries, or bile leaks between groups.

The ACDC trial, which remains the largest single RCT dedicated to this question, randomised 618 patients across centres in Germany and reported a 75-day morbidity rate of 11.8% with immediate surgery versus 34.4% with antibiotics followed by delayed surgery. Notably, conversion rates and mortality were equivalent between groups, reinforcing the view that operating in an acutely inflamed field does not compromise safety when performed by experienced surgeons.

Clinical Pearl

The approximately 10% treatment failure rate observed in delayed-surgery groups across multiple RCTs is often underappreciated. These patients require emergency surgery during the waiting period under less controlled conditions — a risk that early cholecystectomy eliminates entirely.

Hospital Stay and Healthcare Costs: Consistent Advantages for Early Surgery

The most reproducible finding across the entire evidence base is that early cholecystectomy reduces total hospital stay. The ACDC trial demonstrated a mean total stay of 5.4 days versus 10.0 days (p < 0.001), with hospital costs of €2,919 versus €4,262 (p < 0.001). Meta-analyses consistently show total hospital stay reductions in the range of 3–5 days for early versus delayed approaches. Gallagher and colleagues confirmed this in their economic meta-analysis, noting that cost savings were primarily driven by the elimination of readmissions and repeat admissions for recurrent biliary symptoms during the waiting period.

5.4 vs 10 Mean hospital days: early vs delayed (ACDC trial)

~10% Treatment failure rate while awaiting delayed surgery

0.57 RR for wound infections favouring early LC (Cao 2015 MA)

€1,343 Cost saving per patient with early surgery (ACDC)

Optimal Timing Window: Sooner Appears Better, But the Threshold Is Debated

A key area of ongoing discussion concerns whether there is a specific time window within which early cholecystectomy delivers maximum benefit. The ACDC trial used a 24-hour threshold and reported strong results. The 2020 WSES guidelines recommend surgery as soon as possible within 7 days of admission and within 10 days of symptom onset. The Tokyo Guidelines 2018 adopted a broader approach, recommending early surgery regardless of symptom duration, provided the patient's comorbidity profile and surgical expertise are appropriate.

A large 2023 multicentre prospective observational study across 79 centres in 19 countries provides further granularity. Among 1,117 patients who underwent early cholecystectomy within 10 days, those operated on within 0–3 days experienced fewer intraoperative complications (2.8%) than those operated at 4–7 days (5.6%) or 8–10 days (7.9%, p = 0.01). The rate of subtotal cholecystectomy — a marker of surgical difficulty — also rose significantly with delay. However, postoperative complications, conversion rates, and mortality did not differ significantly across the three timing subgroups.

Subgroup: Elderly Patients (Age ≥65)

Older adults have historically been considered higher risk for urgent surgery, leading many centres to prefer a conservative approach. However, several retrospective analyses and the WSES 2017/2019 elderly-focused guidelines suggest that age alone should not preclude early cholecystectomy. Delayed approaches in elderly patients carry additional risks including prolonged immobilisation, deconditioning, and gallstone-related complications during the waiting interval. The available evidence, while largely observational, indicates that early surgery in carefully selected elderly patients is associated with comparable or improved outcomes versus delayed management, provided adequate perioperative optimisation is performed.

Subgroup: High-Risk Patients (APACHE II ≥7)

The CHOCOLATE trial directly addressed this population, randomising 142 high-risk patients to laparoscopic cholecystectomy versus percutaneous catheter drainage. Even in this comorbid cohort, cholecystectomy was associated with a lower rate of the composite primary endpoint (major complications, reintervention, or death within one year). Percutaneous drainage was associated with higher rates of recurrent biliary events and reintervention. The 2020 WSES guidelines now state that early cholecystectomy should be the standard even for most high-risk patients, with the important caveat that this requires experienced surgical teams and appropriate perioperative support. Percutaneous drainage should be reserved for truly inoperable patients — those in septic shock or with absolute anaesthesiological contraindications.

Subgroup: Severe (Grade III) Cholecystitis

Severe cholecystitis with organ dysfunction represents the most challenging subgroup. The Tokyo Guidelines 2018 expanded the surgical indication to include selected Grade III patients — specifically, those with favourable organ system failure, negative predictive factors, CCI ≤3, and ASA-PS ≤2 — but only when surgery is performed at advanced centres by experienced surgeons. No dedicated RCT exists for this subgroup. Available data come from retrospective series and a Japanese prospective study of 201 patients, which found that Grade II/III cases had longer operative times, greater blood loss, and higher major morbidity (10.2%) compared with Grade I (1.8%, p = 0.012). The evidence supports a more cautious, individualised approach for these patients.

Subgroup: Patients Presenting After 72 Hours of Symptoms

Earlier iterations of the Tokyo Guidelines recommended early cholecystectomy only within 72 hours of symptom onset. TG18 removed this time restriction, recommending surgery based on patient fitness and surgical expertise rather than symptom duration. A retrospective study from Egypt found no significant difference in subtotal cholecystectomy rates, conversion rates, bile leak, or length of stay between patients operated within 72 hours versus those operated at 4–10 days from symptom onset. The WSES multicentric study similarly showed that while operative times were longer in the 8–10 day window, postoperative outcomes remained acceptable. The emerging consensus supports operating during the index admission whenever feasible, rather than deferring surgery purely because a time threshold has been crossed.

Quality & Consistency of Evidence

Total hospital stay reduction with early LC: Consistent across all meta-analyses and the largest RCTs (ACDC, n=618). Effect sizes range from 3 to 5 fewer total hospital days. Multiple concordant high-quality sources make this the most robust finding in the evidence base.

Safety equivalence (BDI, conversion, mortality): No meta-analysis or major RCT has identified a statistically significant increase in bile duct injury, conversion to open surgery, or mortality with early cholecystectomy. Confidence intervals are wide due to the rarity of these events, but the direction of evidence is consistent.

Cost-effectiveness of early surgery: Economic analyses within RCTs consistently favour early cholecystectomy, primarily through reduced readmissions. However, the quality of economic evaluations is limited, with few studies accounting for broader societal costs such as lost productivity.

Early LC in high-risk patients: Supported by one well-designed RCT (CHOCOLATE, n=142) and the 2020 WSES guidelines. The evidence base is more limited than for the general population, but the direction of benefit is consistent.

Optimal time threshold within "early" (24 h vs 72 h vs 7 days): Observational data and subgroup analyses suggest earlier is better for intraoperative difficulty, but no RCT has directly compared these windows head-to-head. The evidence remains indirect and mostly retrospective.

Early LC for Grade III (severe) cholecystitis: No dedicated RCT. Available data come from retrospective series and expert consensus. TG18 permits it only at advanced centres under strict criteria.

What the Evidence Does Not Show

Evidence Gaps

Despite the overall strength of the evidence favouring early cholecystectomy, several clinically important questions remain unanswered by existing randomised data.

No RCT has directly compared surgery within 24 hours against surgery at 72 hours or 7 days in a head-to-head design. The existing evidence on finer timing distinctions comes from subgroup analyses and observational studies, which are inherently more prone to confounding. Additionally, no randomised trial has been dedicated exclusively to patients with severe (Grade III) cholecystitis, and the optimal management of these patients remains guided primarily by expert consensus and retrospective data.

Quality-of-life outcomes are notably absent from virtually all published RCTs. The Cochrane review explicitly noted that none of the included trials reported quality of life from the time of randomisation. Patient-reported outcomes such as return to work, pain trajectories, and satisfaction remain poorly characterised. Furthermore, the ability to predict which conservatively managed patients are most likely to experience recurrent biliary events before delayed surgery remains limited — a 2025 systematic review by Salama and colleagues found no reliable clinical predictors of recurrence.

Practical Implications

Based on the current evidence, the following considerations emerge for clinicians managing patients with acute calculous cholecystitis.

Evidence Supports Index-Admission Surgery

Multiple RCTs and meta-analyses indicate that performing laparoscopic cholecystectomy during the index admission — ideally within 7 days — is associated with reduced total hospital stay, lower costs, and fewer gallstone-related complications during a waiting period, without increasing major complication rates.

Earlier Timing Shows Advantages for Surgical Difficulty

Observational data from the large WSES multicentre study suggest that operating within 0–3 days of symptom onset is associated with fewer intraoperative complications and lower rates of bailout procedures compared with 8–10 days, though postoperative outcomes are comparable across the "early" window.

Cholecystectomy Shows Benefits Over Drainage in High-Risk Patients

The CHOCOLATE trial provides evidence that laparoscopic cholecystectomy outperforms percutaneous drainage even in high-risk patients. Drainage should be reserved for the truly inoperable — those in septic shock or with absolute contraindications to general anaesthesia.

Severity Grading Supports Individualised Decision-Making

The available evidence supports using severity grading systems (TG18 or WSES) to stratify management. Grade I and II patients are well-served by early surgery. Grade III patients require careful assessment and should ideally be managed at centres with advanced laparoscopic expertise and bailout procedure capabilities.

Evidence Grade + Bottom Line

Overall Evidence Grade: Strong

The evidence supporting early laparoscopic cholecystectomy for acute cholecystitis in operable patients is based on multiple concordant RCTs (including the ACDC trial, n=618), several meta-analyses pooling over 15 trials, and two major international guidelines. The core findings — equivalent safety and shorter hospital stay — are unlikely to change with further research.

What This Means for Practice

A "strong" evidence grade indicates that the central conclusions are well-supported by high-quality evidence and are unlikely to be overturned by future studies. However, this grade applies specifically to the comparison of early vs delayed surgery in operable patients with Grade I–II cholecystitis. Evidence for finer timing distinctions and for severe-grade disease remains at a lower certainty level.

Bottom Line

Early laparoscopic cholecystectomy during the index admission is at least as safe as delayed surgery and reduces total hospital stay by 3–5 days.
Both the WSES and Tokyo Guidelines now recommend early surgery for operable patients — deferral should be the exception, not the default.
The approximately 10% treatment-failure rate in conservatively managed patients represents an avoidable source of emergency readmissions and unplanned surgery.
High-risk patients benefit from cholecystectomy over percutaneous drainage when they can tolerate general anaesthesia.
Evidence for the optimal timing window within "early" (24 h vs 72 h vs 7 days) and for severe Grade III cholecystitis remains limited and requires further dedicated randomised investigation.

Article Information

For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.

References

Gutt CN, Encke J, Köninger J, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study). Ann Surg. 2013;258(3):385–393. DOI: 10.1097/SLA.0b013e3182a1599b
Pisano M, Allievi N, Gurusamy K, et al. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg. 2020;15(1):61. DOI: 10.1186/s13017-020-00336-x
Okamoto K, Suzuki K, Takada T, et al. Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):55–72. DOI: 10.1002/jhbp.516
Gurusamy KS, Davidson C, Gluud C, Davidson BR. Early versus delayed laparoscopic cholecystectomy for people with acute cholecystitis. Cochrane Database Syst Rev. 2013;(6):CD005440. DOI: 10.1002/14651858.CD005440.pub3
Cao AM, Eslick GD, Cox MR. Early cholecystectomy is superior to delayed cholecystectomy for acute cholecystitis: a meta-analysis. J Gastrointest Surg. 2015;19(5):848–857. DOI: 10.1007/s11605-015-2747-x
Lyu Y, Cheng Y, Wang B, Zhao S, Chen L. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: an up-to-date meta-analysis of randomized controlled trials. Surg Endosc. 2018;32(12):4728–4741. DOI: 10.1007/s00464-018-6400-0
Loozen CS, van Santvoort HC, van Duijvendijk P, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high risk patients (CHOCOLATE): multicentre randomised clinical trial. BMJ. 2018;363:k3965. DOI: 10.1136/bmj.k3965
Gallagher TK, Kelly ME, Hoti E. Meta-analysis of the cost-effectiveness of early versus delayed cholecystectomy for acute cholecystitis. BJS Open. 2019;3(2):146–152. DOI: 10.1002/bjs5.50120
Wakabayashi G, Iwashita Y, Hibi T, et al. Tokyo Guidelines 2018: surgical management of acute cholecystitis: safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):73–86. DOI: 10.1002/jhbp.517
Shetty HS, Amar DN, et al. A randomized controlled study on early and delayed laparoscopic cholecystectomy for acute calculus cholecystitis. Int Surg J. 2025;12(3):333–338. DOI: 10.18203/2349-2902.isj20250560
Salama A, Calpin GG, Fuller R, Hill ADK. Clinical predictors of recurrent cholecystitis in non-operative management: a systematic review & meta-analysis. The Surgeon. 2025;23(2):106–113. DOI: 10.1016/j.surge.2024.11.004
Podda M, Pisanu A, Germani P, et al. Timing of early cholecystectomy for acute calculous cholecystitis: a multicentric prospective observational study. Healthcare. 2023;11(20):2752. DOI: 10.3390/healthcare11202752
Catena F, Coccolini F, Montori G, et al. Clinical update on acute cholecystitis and biliary pancreatitis: between certainties and grey areas. eClinicalMedicine. 2024;77:102880. DOI: 10.1016/j.eclinm.2024.102880